Table 2.
Comparing the management and outcome of mucormycosis between COVID-19 and non-COVID-19 patients
| Variables | Total (n=64) | COVID-19 | P value | |
|---|---|---|---|---|
| Yes (n=43) | No (n=21) | |||
| Involvements | ||||
| Sinus | 38 (100) | 26 (68.4) | 12 (31.6) | 0.799 |
| Orbit | 60 (100) | 39 (65) | 21 (35) | 0.294 |
| Pulmonary | 9 (100) | 7 (77.8) | 2 (22.2) | 0.706 |
| CNS | 4 (100) | 3 (75) | 1 (25) | 1.000 |
| Managements | ||||
| Immunosuppressive | 41 (100) | 32 (78) | 9 (22) | 0.013* |
| Corticosteroid | 33 (100) | 32 (97) | 1 (3) | <0.001 |
| Outcomes | ||||
| Ventilation | 21 (100) | 18 (85.7) | 3 (14.3) | <0.001 |
| In-hospital mortality | 22 (100) | 19 (86.4) | 3 (13.9) | 0.018 |
CNS: central nervous system.